Category: imidazoles-derivatives

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study was written by Rule, Simon;Barreto, Wolney Gois;Briones, Javier;Carella, Angelo M.;Casasnovas, Olivier;Pocock, Chris;Wendtner, Clemens-Martin;Zaja, Francesco;Robson, Susan;MacGregor, Lachlan;Tschopp, Roger R.;Nick, Sonja;Dreyling, Martin. And the article was included in Haematologica in 2022.Related Products of 16506-27-7 The following contents are mentioned in the article:

Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides addnl. benefit. The phase III MabCute study enrolled 692 patients with relapsed or refractory indolent non-Hodgkin lymphoma. Patients who responded to induction with rituximab plus chemotherapy and were still responding after up to 2 years’ initial maintenance with s.c. rituximab were randomized to extended maintenance with s.c. rituximab (n=138) or observation only (n=138). The primary endpoint of investigator-assessed progression-free survival in the randomized population was un-addressed by the end of study because of an insufficient number of events (129 events were needed for 80% power at 5% significance if approx. 330 patients were randomized). In total, there were 46 progression-free survival events, 19 and 27 in the rituximab and observation arms, resp. (P=0.410 by stratified log-rank test; hazard ratio 0.76 [95% confidence interval: 0.37-1.53]). The median progression-free survival was not reached in either randomized arm. There were no new safety signals; however, adverse events were seen slightly more frequently with rituximab than with observation during extended maintenance. Maintenance for up to 2 years with rituximab after response to initial induction therefore remains the standard of care in patients with relapsed or refractory indolent non-Hodgkin lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Optimization and kinetic study of biodiesel production through esterification of oleic acid applying ionic liquids as catalysts was written by Roman, Fernanda F.;Ribeiro, Antonio E.;Queiroz, Ana;Lenzi, Giane G.;Chaves, Eduardo S.;Brito, Paulo. And the article was included in Fuel in 2019.Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

In this study, 1-methylimidazolium hydrogen sulfate, [HMIM]HSO₄, ionic liquid, was successfully applied as a catalyst in the biodiesel production through the esterification reaction of oleic acid with methanol. A response surface methodol. (RSM) known as Box-Behnken Design (BBD) was applied to optimize the main exptl. reaction conditions, using a set of 27 experiments This optimization was based on the maximization of both the conversion of oleic acid and the Fatty Acid Me Esters (FAME) content of the obtained biodiesel samples. It was concluded that the two most relevant parameters for both the conversion and the FAME content were the molar ratio between oleic acid and methanol and the catalyst dosage. Accordingly to the model, the optimum condition for the maximum conversion was determined as being 8 h, 110 ± 2 °C, 15:1 M ratio methanol/oleic acid and a catalyst dosage of 15 wt%, resulting in a 95% conversion and for the maximum FAME content were 8 h, 110 ± 2 °C, 14:1 M ratio and a catalyst dosage of 14 wt%, leading to a FAME content of 90%. The kinetics of the esterification reaction was also evaluated, and the exptl. results were well described using a third-order reaction model. The kinetic parameters were exptl. determined, and the value of the activation energy was 6.8 kJ/mol and the pre-exponential factor was 0.0765 L².mol^-2.min^-1 confirming that the ionic liquid, [HMIM]HSO₄, is a good alternative for replacing traditional catalysts for biodiesel production through esterification reaction. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Coordination polymers constructed by diverse metal centers and the rigid ligand 3,5-di(1H-imidazol-1-yl)pyridine. Synthesis, structure and properties was written by Luo, Li;Zhao, Yue;Lu, Yi;Okamura, Taka-aki;Sun, Wei-Yin. And the article was included in Polyhedron in 2012.COA of Formula: C11H9N5 The following contents are mentioned in the article:

Six new coordination polymers, [Cu(L)₂(H₂O)₂](NO₃)₂ (I), [Cu(L)₂](ClO₄)₂ (II), [Cd(L)₂(H₂O)₂](ClO₄)₂ (III), [Cd(L)(OAc)₂(H₂O)] (IV), [Cu₃(L)₄(H₂O)₂(SO₄)](SO₄)₂.30H₂O (V), and [Ni(L)(H₂O)₃(SO₄)] (VI) [L = 3,5-di(1H-imidazol-1-yl)pyridine, OAc^– = MeCOO^–], were prepared and characterized by x-ray diffraction, IR, elemental and thermogravimetric analyses. Complexes I, IV, and VI have different 1D chain structures, while II and III are 2D networks. The chains and layers are further linked together by H-bonds to generate 3D frameworks. Complex V is a (3,4,4)-connected 3D framework with a Point (Schlaefli) symbol of (4.8²)₄(4.8³.10²)₂(4².8².10²). The influences of the coordination modes of the ligand L, metal center as well as the counteranion on the structures of the complexes are discussed. Furthermore, the reversible anion exchange property of III and the photoluminescence properties of III and IV were investigated. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6COA of Formula: C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.COA of Formula: C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Performance and Mechanism of Alkylimidazolium Ionic Liquids as Corrosion Inhibitors for Copper in Sulfuric Acid Solution was written by Tian, Guocai;Yuan, Kaitao. And the article was included in Molecules in 2021.SDS of cas: 478935-29-4 The following contents are mentioned in the article:

The addition of corrosion inhibitors is an economic and environmental protection method to prevent the corrosion of copper. The adsorption, performance, and mechanism of three 1-alkyl-3-methylimidazolium hydrogen sulfate ([BMIM]HSO4, [HMIM]HSO4, and [OMIM]HSO4) ionic liquids (ILs) on the copper surface in 0.5 M H₂SO₄ solutions were studied by quantum chem. calculation, quant. structure-activity relationship (QSAR), and mol. dynamics simulation. It is found that the main reactive site is located on the imidazolium ring (especially the C2, N4, and N7 groups). When the alkyl chain of the imidazolium ring is increasing, the mol. reactivity of the ILs and the interaction between the ILs inhibitor and copper surface are enhanced. The imidazole ring of the ILs tends to be adsorbed on Cu (111) surface in parallel through phys. adsorption. The order of adsorption energy is [Bmim]HSO4 < [Hmim]HSO4 < [OMIM]HSO4, which is in agreement with the exptl. order of corrosion efficiency. On the imidazole ring, the interaction between the copper surface and the C atom is greater than that between the copper surface and the N atom. It is found that ILs addition can hinder the diffusion of corrosion particles, reduce the number d. of corrosion particles and slow down the corrosion rate. The order of inhibition ability of three ILs is [Bmim]HSO4 < [Hmim]HSO4 < [OMIM]HSO4,which agree well with exptl. results. A reliable QSAR correlation between the inhibition corrosion efficiency and mol. reactivity parameters of the ILs was established. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4SDS of cas: 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.SDS of cas: 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups was written by Bastos-Oreiro, Mariana;Gutierrez, Antonio;Reguera, Juan Luis;Iacoboni, Gloria;Lopez-Corral, Lucia;Terol, Mara Jose;Ortiz-Maldonado, Valentin;Sanz, Jaime;Guerra-Dominguez, Luisa;Bailen, Rebeca;Mussetti, Alberto;Abrisqueta, Pau;Hernani, Rafael;Luzardo, Hugo;Sancho, Juan-Manuel;Delgado-Serrano, Javier;Salar, Antonio;Grande, Carlos;Bento, Leyre;de Villambrosa, Sonia Gonzalez;Garcia-Belmonte, Daniel;Sureda, Anna;Perez-Martinez, Antonio;Barba, Pere;Kwon, Mi;Garcia-Sancho, Alejandro Martin. And the article was included in Frontiers in Immunology in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with com. CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 mo, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 mo, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001 for PFS, and 0.45 (95% CI: 0.31-0.64) for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 vs. 2.8 mo, resp., p = 0.027) and OS (58% vs. 42% at 12 mo, resp., p = 0.048) than tisa-cel. These differences were maintained in the multivariable anal. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases was written by Chen, Yao;Liu, Qingyi;Hu, Fulian;Ma, Jizheng. And the article was included in MicrobiologyOpen in 2020.Formula: C18H20N3NaO3S The following contents are mentioned in the article:

The treatment regimen for the eradication of Helicobacter pylori may be best when therapy is susceptibility guided. However, it is unrealistic to use a strategy based on susceptibility testing to prioritize therapy for every patient in China. Empirical therapy of H. pylori is still widely used. The study was designed to discuss the best first-line treatment regimen depending on empirical therapy. The focal point of the study was the optimal length of the therapy. Also, the selection of antibiotics was discussed in the article. This was a prospective, randomized, non-inferiority trial. H. pylori-infected patients who have no previous eradication therapy were randomly assigned to the following: 20 mg of rabeprazole, 1000 mg of amoxicillin, 500 mg of clarithromycin, and 220 mg of bismuth potassium citrate (BACPPI), administered twice a day for 10 or 14 days. The efficacy, side effects, and remission rate of clin. symptoms were determined A total of 240 subjects were included in the study. The eradication rate with 14 and 10 days was essentially identical in both intention-to-treat (90.83% [95% CI, 86%-96%] vs. 87.50% [95% CI, 82%-93%]) and per-protocol (94.78% [95% CI, 91%-99%] vs. 92.11% [95% CI, 87%-97%]) analyses. Loss of appetite and belching symptoms were significantly better in the BACPPI-10 group than those in the control group after treatment. Side effects were generally mild and similar between groups. Our results showed that a 10-day amoxicillin-clarithromycin-containing bismuth quadruple therapy may be recommended for the primary empirical treatment of H. pylori infection in Beijing, China. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Analysis of potential genotoxic impurities in rabeprazole active pharmaceutical ingredient via Liquid Chromatography-tandem Mass Spectrometry, following quality-by-design principles for method development was written by Iliou, Katerina;Malenovic, Andjelija;Loukas, Yannis L.;Dotsikas, Yannis. And the article was included in Journal of Pharmaceutical and Biomedical Analysis in 2018.SDS of cas: 117976-90-6 The following contents are mentioned in the article:

A novel Liquid Chromatog.-tandem mass spectrometry (LC-MS/MS) method is presented for the quant. determination of two potential genotoxic impurities (PGIs) in rabeprazole active pharmaceutical ingredient (API). In order to overcome the anal. challenges in the trace anal. of PGIs, a development procedure supported by Quality-by-Design (QbD) principles was evaluated. The efficient separation between rabeprazole and the two PGIs in the shortest anal. time was set as the defined anal. target profile (ATP) and to this purpose utilization of a switching valve allowed the flow to be sent to waste when rabeprazole was eluted. The selected critical quality attributes (CQAs) were the separation criterion s between the critical peak pair and the capacity factor k of the last eluted compound The effect of the following critical process parameters (CPPs) on the CQAs was studied: %ACN content, the pH and the concentration of the buffer salt in the mobile phase, as well as the stationary phase of the anal. column. D-Optimal design was implemented to set the plan of experiments with UV detector. In order to define the design space, Monte Carlo simulations with 5000 iterations were performed. Acceptance criteria were met for C₈ column (50 × 4 mm, 5 μm), and the region having probability π ≥ 95% to achieve satisfactory values of all defined CQAs was computed. The working point was selected with the mobile phase consisting of ACN, ammonium formate 11 mM at a ratio 31/69 volume/volume with pH = 6,8 for the water phase. The LC protocol was transferred to LC-MS/MS and validated according to ICH guidelines. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6SDS of cas: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. SDS of cas: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment strategies for patients with diffuse large B-cell lymphoma was written by Poletto, Stefano;Novo, Mattia;Paruzzo, Luca;Frascione, Pio Manlio Mirko;Vitolo, Umberto. And the article was included in Cancer Treatment Reviews in 2022.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline treatment R-CHOP, but 30-40% of patients are still unresponsive or relapse thereafter. In the recent era several upcoming new options are improving the therapeutic landscape for relapsed/refractory (R/R) DLBCL setting, first of all anti-CD19 chimeric antigen receptor T-cells (CAR-T) that already represent a standard of care as third-line therapy and are rapidly moving as second-line treatment for those who are refractory or early relapse after R-CHOP. Among these new therapies, the combinations polatuzumab plus rituximab and bendamustine, tafasitamab plus lenalidomide for transplant ineligible patients, and CD3xCD20 bispecific antibodies are the most relevant, but several other agents and strategies are on the way. On the other hand, in the last 20 years, several efforts have been spent in the attempt to ameliorate the outcome over R-CHOP for the frontline treatment of DLBCL shortening the interval between the cycles or intensifying treatment or adding novel drugs to R-CHOP without success, so far. Recent studies combining the anti-CD79b antibody-drug conjugate polatuzumab vedotin plus R-CHP and the anti-BCL2 agent venetoclax plus R-CHOP showed promising results. Preliminary data of new upcoming strategies characterized by a tailored therapy based on different mol. subtypes of DLBCL are encouraging, showing a benefit over the standard R-CHOP. In this manuscript, the literature data on the landscape of new therapies available and upcoming for both frontline and R/R settings of DLBCL will be critically reviewed. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database. was written by Watanabe, Ayako;Momo, Kenji;Tanaka, Katsumi;Uchikura, Takeshi;Kiryu, Yoshihiro;Niiyama, Kanami;Kodaira, Norihisa;Matsuzaki, Airi;Sasaki, Tadanori. And the article was included in Biological & pharmaceutical bulletin in 2022.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

This study aimed to identify the components of proton pump inhibitors (PPIs) or potassium-competitive acid blocker (PCAB) that lead to cardiovascular events in individuals of working age. We analyzed large claims data of individuals who were administered PPIs or PCAB. We enrolled working-age individuals administered PPI or PCAB without cardiovascular history with a 12-month screening and 12-month observation period and determined the proportion of cardiovascular events and the predictive factors of cardiovascular events in this population. Among the eligible individuals, 0.5% (456/91098) had cardiovascular events during the 12-month observation period. Predictive factors for cardiovascular events were age for +1 year (p < 0.0001), male sex (p < 0.0001), hypertension (p = 0.0056), and diabetes mellitus (p < 0.0001). The cardiovascular disease risk was higher in working-age individuals administered lansoprazole than in those administered other drugs (vs. rabeprazole; p = 0.0002, vs. omeprazole; p = 0.0046, vs. vonoprazan; p < 0.0001, and vs. esomeprazole; p < 0.0001). We identified the risk for cardiovascular events in individuals being treated with lansoprazole. Lansoprazole is known for its higher CYP2C19 inhibition activity compared with other PPIs or PCAB. A possible mechanism by which lansoprazole may lead to cardiovascular events is inhibiting the generation of epoxyeicosatrienoic acids from arachidonic acids, an intrinsic cardioprotective activator via CYP2C19 inhibition. Thus, we recommend avoiding administering lansoprazole to working-age individuals require PPIs or PCAB. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells was written by Xie, Jing;Fan, Long;Xiong, Liya;Chen, Peiyu;Wang, Hongli;Chen, Huan;Zhao, Junhong;Xu, Zhaohui;Geng, Lanlan;Xu, Wanfu;Gong, Sitang. And the article was included in BMC Pharmacology and Toxicology in 2021.Formula: C18H20N3NaO3S The following contents are mentioned in the article:

Abstract: Background: Helicobacter pylori (H. pylori) is a common pathogen in development of peptic ulcers with pyroptosis. Rabeprazole, a critical component of standard triple therapy, has been widely used as the first-line regimen for H. pylori infectious treatment. The aim of this study to explore the function of Rabeprazole on cell pyroptosis in vitro. Methods: The clin. sample from patients diagnosed with or without H. pylori-infection were collected to analyze by Immunohistochem. (IHC). Real-time quant. PCR (qPCR), western blot (WB) and enzyme linked immunosorbent assay (Elisa) were performed to analyze the effect of Rabeprazole on cell pyroptosis, including LDH, IL-1β and IL-18. Results: In this study, we showed that Rabeprazole regulated a phenomenon of cell pyroptosis as confirmed by lactate dehydrogenase (LDH) assay. Further results showed that Rabeprazole inhibited cell pyroptosis in gastric epithelial cells by alleviating GSDMD-executed pyroptosis, leading to decrease IL-1β and IL-18 mature and secretion, which is attributed to NLRP3 inflammasome activation inhibition. Further anal. showed that ASC, NLRP3 and Caspase-1, was significantly repressed in response to Rabeprazole stimulation, resulting in decreasing cleaved-caspase-1 expression. Most important, NLRP3 and GSDMD is significantly increased in gastric tissue of patients with H. pylori infection. Conclusion: These findings revealed a critical role of Rabeprazole in cell pyroptosis in patients with H. pylori infection, suggesting that targeting cell pyroptosis is an alternative strategy in improving H. pylori treatment. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem